The prevalence and spectrum of BRCA1 and BRCA2 mutations in Korean population: recent update of the Korean Hereditary Breast Cancer (KOHBRA) study

[1]  Sung-Won Kim,et al.  A multi-institutional study of the prevalence of BRCA1 and BRCA2 large genomic rearrangements in familial breast cancer patients , 2014, BMC Cancer.

[2]  Sun Young Min,et al.  The Basic Facts of Korean Breast Cancer in 2011: Results of a Nationwide Survey and Breast Cancer Registry Database , 2014, Journal of breast cancer.

[3]  V. Moyer.  Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement. , 2014, Annals of internal medicine.

[4]  Jeong Eon Lee,et al.  The prevalence of BRCA mutations among familial breast cancer patients in Korea: results of the Korean Hereditary Breast Cancer study , 2013, Familial Cancer.

[5]  S. Teo,et al.  Triple-negative breast cancer and PTEN (phosphatase and tensin homologue)loss are predictors of BRCA1 germline mutations in women with early-onset and familial breast cancer, but not in women with isolated late-onset breast cancer , 2012, Breast Cancer Research.

[6]  S. Ahn,et al.  Characteristics and spectrum of BRCA1 and BRCA2 mutations in 3,922 Korean patients with breast and ovarian cancer , 2012, Breast Cancer Research and Treatment.

[7]  Jeong Eon Lee,et al.  Prevalence of BRCA1 and BRCA2 mutations in non-familial breast cancer patients with high risks in Korea: The Korean Hereditary Breast Cancer (KOHBRA) Study , 2012, Breast Cancer Research and Treatment.

[8]  D. Noh,et al.  The Korean Hereditary Breast Cancer (KOHBRA) study: protocols and interim report. , 2011, Clinical oncology (Royal College of Radiologists (Great Britain)).

[9]  S. Neuhausen,et al.  Mutations in BRCA2 and PALB2 in male breast cancer cases from the United States , 2011, Breast Cancer Research and Treatment.

[10]  D. Evans,et al.  Genetic testing for familial/hereditary breast cancer—comparison of guidelines and recommendations from the UK, France, the Netherlands and Germany , 2011, Journal of Community Genetics.

[11]  D. Evans,et al.  Risk of breast cancer in male BRCA2 carriers , 2010, Journal of Medical Genetics.

[12]  Montserrat Garcia-Closas,et al.  Genetic susceptibility to breast cancer , 2010, Molecular oncology.

[13]  D. Noh,et al.  Comprehensive mutational analysis of BRCA1/BRCA2 for Korean breast cancer patients: evidence of a founder mutation , 2009, Clinical genetics.

[14]  Stephanie A Cohen,et al.  The prevalence of BRCA1 mutations among young women with triple-negative breast cancer , 2009, BMC Cancer.

[15]  Giovanni Parmigiani,et al.  Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. , 2007, Journal of the National Cancer Institute.

[16]  Olufunmilayo I. Olopade,et al.  Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations , 2007, Nature Reviews Cancer.

[17]  W. Han,et al.  BRCA1 and BRCA2 germline mutations in Korean breast cancer patients at high risk of carrying mutations. , 2007, Cancer letters.

[18]  K.‐R. Lee,et al.  Mutation analysis of BRCA1 and BRCA2 from 793 Korean patients with sporadic breast cancer , 2006, Clinical genetics.

[19]  T. Walsh,et al.  Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. , 2006, JAMA.

[20]  S. Ahn,et al.  BRCA1 and BRCA2 germline mutations in Korean patients with sporadic breast cancer , 2004, Human mutation.

[21]  D. Horn,et al.  Screening for large rearrangements of the BRCA1 gene in German breast or ovarian cancer families using semi‐quantitative multiplex PCR method , 2003, Human mutation.

[22]  Adopted on March.  American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  U. Hamann,et al.  Similar contributions of BRCA1 and BRCA2 germline mutations to early-onset breast cancer in Germany , 2003, European Journal of Human Genetics.

[24]  A. Aurias,et al.  Significant contribution of large BRCA1 gene rearrangements in 120 French breast and ovarian cancer families , 2002, Oncogene.

[25]  D. Noh,et al.  Germline mutations of BRCA1 and BRCA2 in Korean breast and/or ovarian cancer families , 2002, Human mutation.

[26]  G. Parmigiani,et al.  Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families , 2002, Journal of medical genetics.

[27]  E. Wilkinson.  Cancer Research UK , 2002 .

[28]  Douglas F Easton,et al.  BRCA1 and BRCA2 mutations in a population-based study of male breast cancer , 2001, Breast Cancer Research.

[29]  E. Ostrander,et al.  Frequency of BRCA1/BRCA2 mutations in a population‐based sample of young breast carcinoma cases , 2000, Cancer.

[30]  S. Seal,et al.  Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. , 1999, Journal of the National Cancer Institute.

[31]  D. Stoppa-Lyonnet,et al.  Screening for germ-line rearrangements and regulatory mutations in BRCA1 led to the identification of four new deletions. , 1999, Cancer research.

[32]  M. King,et al.  Population genetics of BRCA1 and BRCA2. , 1997, American journal of human genetics.

[33]  B. Ponder,et al.  Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. , 1997, American journal of human genetics.

[34]  J. Rommens,et al.  BRCA2 germline mutations in male breast cancer cases and breast cancer families , 1996, Nature Genetics.

[35]  D. Bentley,et al.  Identification of the breast cancer susceptibility gene BRCA2 , 1995, Nature.

[36]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.